Interferon alpha-5

Drug Profile

Interferon alpha-5

Alternative Names: IFN-α5; NAHE 001

Latest Information Update: 30 Sep 2015

Price : $50

At a glance

  • Originator Digna Biotech
  • Class Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 30 Sep 2015 Phase-II clinical trials in Hepatitis C in Spain (SC)
  • 31 Jan 2013 Digna Biotech completes a phase I/II trial in Hepatitis C in Spain (NCT01121731)
  • 26 May 2011 Pro-Pharmaceuticals is now called Galectin Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top